Novo Nordisk

Novo Nordisk completed and donated a $40 million regional industrial wastewater pretreatment facility to the Town of Clayton, North Carolina. The facility will serve Novo Nordisk's API manufacturing plant and can be expanded to treat 450,000 gallons per day for other biopharma companies.

Nemera and Novo Nordisk laid the foundation stone for a new manufacturing hall (Hall 6) at Nemera's headquarters in La Verpillière, France, on March 21, 2019. The hall will produce injected plastic parts for Novo Nordisk's pen needles.

Novo Nordisk will invest $1.2 billion to build new bio-manufacturing operations at its Clayton, North Carolina campus to produce the active ingredient for its insulin products. The project will create 691 jobs.

Novo Nordisk will invest $22 million at its Diabetes Finished Products manufacturing facility in Clayton, North Carolina, creating 22 full-time jobs. The expansion follows a $65 million investment announced ten months earlier.

Novo Nordisk officially opened its first tablet production facility in Måløv, Denmark, on June 26, 2018. The plant will produce semaglutide tablets for type 2 diabetes patients.

Emerson has won a $40 million contract to provide automation systems and services for Novo Nordisk's new $2 billion pharmaceutical plant in Clayton, North Carolina, expected to start operations in 2020.

Novo Nordisk awarded Emerson a $40 million automation systems and services contract for its new $2 billion drug manufacturing facility in Clayton, North Carolina, targeting operational readiness by 2020.

Fluor Corp. has been awarded an engineering, procurement, construction and construction management contract by Novo Nordisk for its new $2 billion diabetes active pharmaceutical ingredient manufacturing facility in Clayton, North Carolina.